Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer

DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast Track Designation from FDAClinical entry ...
Medical Xpress

Predicting condensate formation by cancer-associated fusion oncoproteins

Many cancers are caused by fusion oncoproteins, molecules that aberrantly form when a rearrangement of DNA results in parts of two different proteins being expressed as one. Several fusion ...
The Manila Times

Dewpoint Therapeutics Selects First-in-Class MYC Condensate Modulator Development Candidate

Dewpoint Therapeutics, Inc., a biotechnology company pioneering condensate-modulating therapeutics, today announced the ...
EurekAlert!

Reversible manipulation of liquid-liquid phase separation using a chemical-based chemiDroplet

Chemidroplet is a chemical tool, that fused the BTB-containing domain to the multivalent DNA binding domain (DBD) and intrinsically disordered regions (IDRs) to readily control the LLPS of these ...
EurekAlert!

The Goldilocks Effect: Syracuse researchers establish framework for protein regulation

From plants to animals, all living things depend on proteins to help their cells function properly. In certain cases, like when under stress in response to heat or toxins, some proteins within the ...
Pharmabiz

Dewpoint Therapeutics doses first patient in phase 1a/2a clinical trial of DPTX3186 to treat advanced solid tumours

Dewpoint Therapeutics doses first patient in phase 1a/2a clinical trial of DPTX3186 to treat advanced solid tumours: Boston Monday, February 9, 2026, 18:00 Hrs [IST] Dewpoint Ther ...
Science Daily

The Goldilocks Effect: Researchers establish framework for protein regulation

Researchers are working to understand how protein quality control works in cells. From plants to animals, all living things depend on proteins to help their cells function properly. In certain cases, ...